Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Contact information
Claudio Hidalgo Cantabrana, PhD
claudio.hidalgo@microviable.com
(+34)670034435
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IonQ and CCRM Announce Strategic Quantum-Biotech Collaboration to Accelerate Development of Advanced Therapeutics1.12.2025 14:30:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutic development using hybrid quantum and quantum-AI technologies. The partnership includes an investment commitment into CCRM’s new quantum-biotech initiatives and establishes IonQ as the core technology partner across CCRM’s global network of advanced therapy hubs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201706303/en/ IonQ serves as strategic quantum technology partner across CCRM’s leading global regenerative medicine network. With more than 100,000 square feet of good manufacturing practice (GMP) facilities, 300+ scientific staff and a global network of academic and industry partners, CCRM is one of the world’s leading accelerators for advanced therapies. CCRM was established in 2011 in Toronto, Canada, to rea
Ares Management Introduces Marq to Further Unify its Global Logistics Platform Within its Real Estate Business1.12.2025 13:00:00 EET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that it is consolidating its global logistics real estate platforms under a single brand, Marq Logistics (“Marq”). The newly launched brand, Marq, will represent Ares’ vertically integrated global logistics real estate platform managing facilities that total more than 600 million square feet across the Americas, Europe and APAC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201173799/en/ Marq brings together Ares’ vertically integrated logistics real estate platform in North America and Europe, including Ares Industrial Management, with the global GLP logistics real estate platform outside of China. This follows Ares’ acquisition of the international business and certain affiliates of GLP Capital Partners Limited, which closed in March 2025. With Marq, Ares combines its scale, expertise and integrated logis
Prodalim Continues Its Accelerated Strategic Transformation With the Acquisition of René Laurent, a Leading Beverage Flavours Company Based in Grasse area, France1.12.2025 12:42:00 EET | Press release
Prodalim, a global leader in Juice and specialty ingredients solutions, announced today the acquisition of René Laurent, a leading beverage flavours company, from International Flavours & Fragrances Inc. (IFF). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126582710/en/ René Laurent site, Le Cannet, France Established in 1885 in Grasse area, the capital of the flavours and fragrances industry in southern France, René Laurent is a century-old, trusted brand specializing in beverage flavours solutions and unique aromatic Ingredients. The company partners with leading multinational customers and local champions in the beverage industry, offering deep expertise in complex, tailor-made flavour development, including syrups, liqueurs, naturals and coffee. Its extensive flavour library and distinctive in-house distillation and extraction capabilities make René Laurent a respected expert in complex and customized formulations. R
PUMA Opens its Biggest European Flagship Store in the Heart of London, Bringing the Best of the Brand Closer to Consumers1.12.2025 10:00:00 EET | Press release
PUMA has opened the doors to its largest-ever European flagship store on Oxford Street in London, which will bring the best of the company’s products and immersive storytelling closer to consumers in one of the busiest shopping destinations in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201979895/en/ PUMA has opened the doors to its largest-ever European flagship store on Oxford Street in London, which will bring the best of the company’s products and immersive storytelling closer to consumers in one of the busiest shopping destinations in Europe. The new flagship store, located just seconds from Selfridges and Bond Street Tube Station, spans 24,000 square-feet and features PUMA’s industry-leading innovations, such as running technology NITRO™, its football boots FUTURE, ULTRA and KING, as well as its current range of lifestyle products. “The opening of our Oxford Street flagship is an exciting moment for PUMA,
Wayve Acquires Quality Match to Strengthen Data Quality and Safety for AI Driving Systems1.12.2025 10:00:00 EET | Press release
Wayve, the leader in Embodied AI for autonomous driving, today announced the acquisition of Quality Match, a German startup known for its expertise in data quality assurance for computer vision datasets and artificial intelligence. This acquisition reflects Wayve's continued investment in data accuracy as a cornerstone of safe and scalable autonomous driving. Founded in 2019, Quality Match brings deep expertise in interpreting and analysing data used to train AI models for applications such as advanced assisted and automated driving. As Wayve advances toward the commercial deployment of its AI Driver software, integrating Quality Match strengthens its ability to efficiently develop high-quality, auditable datasets that are essential for building reliable and explainable AI models. Quality Match’s team of 20 specialists, based in Germany, will join Wayve's global operations. The acquisition expands Wayve's presence in the country following the launch of its Testing and Development Hub n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom